Livzon Pharmaceutical Group Inc (000513) Fair Value & Analysis
Healthcare · CN · Market cap 27.1B CNY (≈ $4.0B) · ISIN CNE0000002Y8
What is Livzon Pharmaceutical Group Inc really worth?
A strong business, trading 46% below our fair value of ¥49.84.
Strengths
Risks
For context
Fair value as of: Aug 13, 2026
From 26 valuation models · updated 22 days ago
Share price −11.9% over the past month.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The rarer combination: high quality (80/100) AND below fair value. That earns a closer look rather than a quick verdict.
- The price is below even our cautious bear case (¥37.38). The market is more pessimistic than our downside scenario.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range ¥25.54 – ¥43.76 · fair‑value band ¥37.38 – ¥62.30 · the ¥26.77 price screens below the ¥49.84 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 13, 2026.
Analysis
Livzon Pharmaceutical Group Inc (000513) currently trades at ¥26.77, while our model-based Fair Value estimate is ¥49.84, implying the stock looks roughly 46.3% undervalued today. The Quality Score stands at 80/100 (high quality), in the Healthcare sector. Bull case: the DCF Models group reads highest at a median of ¥66.52 per share, and 20 of the 26 models we run sit above the ¥26.77 price. Bear case: the Asset-Based group reads lowest at ¥10.42, and 6 of the 26 models stay below the price. Evidence for this calculation is high.
Over the trailing twelve months, Livzon Pharmaceutical Group Inc generated revenue of 11.7B CNY at a net margin of 16.8%. Revenue declined 9.7% year over year. It earns a return on equity of 15.1%. The balance sheet holds a net cash position of 5.5B CNY. Fundamentals as of Aug 13, 2026
Our scenario range runs from ¥37.38 (bear case) to ¥62.30 (bull case); at ¥26.77, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 40% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −45% fair-value upside, at 86%, 000513 screens cheaper than that median.
Fair Value models
This estimate rests on fiscal year 2025 figures, and about 8 months have passed since. In that time the company retained roughly ¥0.5300 per share, which is 1.1 % of the fair value. The fair value deliberately does not add this in: the models value reported figures, not a projection.
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.
All 26 models by family
Widest divergence: DCF Models (¥66.52) versus Asset-Based (¥10.42). Highest evidence: FCF DCF (78).
Notify me when 000513 reaches fair value
Put 000513 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Free, no payment details. Unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 78 · Market factors (momentum, volatility) 37
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Livzon Pharmaceutical Group Inc. researches, develops, produces, exports, and sells pharmaceutical products, and active pharmaceutical ingredients (API) and intermediates in the People's Republic of China and internationally.
Full company description
Livzon Pharmaceutical Group Inc. researches, develops, produces, exports, and sells pharmaceutical products, and active pharmaceutical ingredients (API) and intermediates in the People's Republic of China and internationally. The company offers leuprorelin acetate microspheres, urofollitropin, and menotropins for injection for the assisted reproduction field; Ilaprazole enteric-coated tablets, ilaprazole sodium for injection, and bismuth potassium citrate products for the gastrointestinal field; fluvoxamine maleate for the psychiatric and neurological field; and shenqi fuzheng injection and anti-viral granules for the traditional Chinese medicine field. It also produces APIs and intermediates, such as mevastatin, acarbose, teicoplanin, gentamycin sulfate, phenylalanine, vancomycin hydrochloride, daptomycin, milbemycin oxime, and ceftriaxone sodium, as well as diagnostic reagents such as diagnostic kits for IgM antibody to mycoplasma pneumonia; diagnostic kits for human immunodeficiency virus antibody; and livzon antinuclear antibody test kits. In addition, the company offers nucleic acid test kits; livzon interferon-gamma release assays test kits; influenza A/B virus antigen detection kits; and treponema pallidum antibody detection kits. Further, it provides biochemical drugs, microbiological preparations, biologic products, Chinese drug preparations and pharmaceutical raw materials, stomatitis granules, biochemical and polypeptide APIs, and antibiotic APIs, as well as diagnostic equipment. Livzon Pharmaceutical Group Inc. was incorporated in 1985 and is headquartered in Zhuhai, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Livzon Pharmaceutical Group Inc reported revenue of 11.9B CNY in FY2025 versus 12.1B CNY in FY2021, a compound −0.3%/yr. Reported net income was 2.0B CNY in FY2025, compounding +3.3%/yr from FY2021.
of which total revenue +6.9 % · buybacks/dilution −0.7 %
Annual growth per factor. These are factors, not summands: multiplied they give the EPS growth rate, added they do not quite. Start and end points are 3-year averages (details on hover).
Watch 000513: get an alert when its fair value changes →
Peer Group
Drug Manufacturers - Specialty & Generic · 608 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Strength profile in five axes (Snowflake)
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Insider activity: 40/100
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Merck KGaA MRK | €140.25 | €106.48 | −24% |
| Takeda Pharmaceutical Company TAK | $18.03 | $11.11 | −38% |
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥53.76 | ¥25.94 | −52% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,944 | ₹989.50 | −49% |
| Galderma Group GALD | CHF 178.55 | CHF 55.07 | −69% |
| Haleon plc HLN | $10.11 | $7.64 | −24% |
| Teva Pharmaceutical Industries Limited TEVA | $36.05 | $15.33 | −57% |
| Sandoz Group SDZ | CHF 70.66 | CHF 39.21 | −45% |
| Zoetis Inc ZTS | $77.10 | $104.88 | +36% |
| Hansoh Pharmaceutical Group 3692 | HK$35.12 | HK$16.18 | −54% |
Compare Livzon Pharmaceutical Group Inc with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Livzon Pharmaceutical Group Inc (000513) overvalued or undervalued?
What is the fair value of 000513?
What is the quality score of 000513?
What is the revenue of Livzon Pharmaceutical Group Inc (000513)?
What is the net profit margin of 000513?
Does Livzon Pharmaceutical Group Inc pay a dividend?
Watch Livzon Pharmaceutical Group Inc in the live analysis
One click puts Livzon Pharmaceutical Group Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.